Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Pharma Univ. WRN compound 14c
- Development stage
- Unknown
- Lead developer
- China Pharmaceutical University
01
Overview
China Pharma Univ. WRN compound 14c: sourced facts only. name: "Mechanistic studies revealed that 14c covalently conjugates to C727 within the WRN helicase domain, forming an adamantane-tagged adduct that initiates sustained proteasomal degradation." [PMID:40921117]; target: "Mechanistic studies revealed that 14c covalently conjugates to C727 within the WRN helicase domain, forming an adamantane-tagged adduct that initiates sustained proteasomal degradation." [PMID:40921117]; developer: "State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, PR China." [PMID:40921117]
02
Targets
WRN (Werner syndrome ATP-dependent helicase)
Beyond the preview
Go deeper on China Pharma Univ. WRN compound 14c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Pharma Univ. WRN compound 14c.